Retroperitoneal robotic partial nephrectomy with the Versius system: a case series [0.03%]
Versius系统下腹腔后机器人部分肾切除术：一系列病例报告
Nazario Foschi,Mauro Ragonese,Pierluigi Russo et al.
Nazario Foschi et al.
Rethinking biopsy timing in renal mass ablation: aligning evolving guidelines with personalized care [0.03%]
肾肿瘤消融活检时机的再思考：与时俱进与个性化治疗相结合的新指南
Riccardo Bertolo,Giovanni Puppini,Andrea Minervini et al.
Riccardo Bertolo et al.
Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center [0.03%]
机器人辅助根治性膀胱切除术二十年生存结果的演变——一家大型三甲机器人手术中心的经验报告
Stefano Resca,Simone Morra,Nicola Frego et al.
Stefano Resca et al.
Background: Radical cystectomy (RC) is the gold standard for muscle-invasive and recurrent high-risk non-muscle-invasive bladder cancer (BCa). Over time, robot-assisted radical cystectomy (RARC) has gained adoption. Despi...
Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 Registry [0.03%]
ROBUUST 2.0登记处的现实世界多中心管理上尿路尿路上皮癌遵守国际指南的见解
Mariaconsiglia Ferriero,Gabriele Tuderti,Flavia Proietti et al.
Mariaconsiglia Ferriero et al.
Background: The European Association of Urology (EAU), American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) guidelines (GL) represent key international standards for clinical practice. We...
Multicenter Study
Minerva urology and nephrology. 2026 Apr;78(2):241-248. DOI:10.23736/S2724-6051.26.06684-X 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study) [0.03%]
基于免疫的联合疗法治疗转移性肾细胞癌的疗效和安全性的真实世界研究
Marco Maruzzo,Alexandr Poprach,Sebastiano Buti et al.
Marco Maruzzo et al.
Background: Nowadays, systemic treatment with immune-based combinations for metastatic renal cell carcinoma (mRCC) is the gold standard. However, the benefit of these treatments in patients aged ≥70 years is uncertain. T...
Comparative Study
Minerva urology and nephrology. 2026 Apr;78(2):210-221. DOI:10.23736/S2724-6051.25.06360-8 2026
Pharmacology, efficacy and safety of different extracts of Serenoa repens in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a narrative review [0.03%]
药物学、疗效和不同提取物的Serenoa repens在下尿路症状和良性前列腺增生患者中的安全性：叙述性综述
Cosimo DE Nunzio,Riccardo Lombardo,Antonio Franco et al.
Cosimo DE Nunzio et al.
Aim of this review is to evaluate the pharmacological efficacy and safety of Serenoa repens extracts in managing lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Using PubMed, Web of Science, and the Cochrane data...
Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review [0.03%]
非肌层浸润性膀胱癌患者经尿道肿瘤切除术后卡介苗方案延迟或未足量给药的不良影响：一项系统综述
Ettore DI Trapani,Arturo Lo Giudice,Elio Mazzone et al.
Ettore DI Trapani et al.
Introduction: Bacillus Calmette-Guérin (BCG) immunotherapy remains the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). While the European Association of Urology (EAU) guidelines recommend ini...
YAU-RCC insights from ESMO 2025: time to refine systemic treatment strategies in renal cell carcinoma [0.03%]
2025年ESMO会议的肾细胞癌系统治疗策略优化——YAU-RCC研究见解
Laura Marandino,Veronica Mollica,Daniele Amparore et al.
Laura Marandino et al.
The data dividend: how AI turns robotic surgery into measurable value. Insight from EAU-YAU Urotechnology and Digital Health Working Group [0.03%]
数据分红：人工智能如何将机器人手术转化为可衡量的价值。来自欧洲泌尿外科-青年泌尿外科协会“尿路技术与数字医疗工作组”的观点
Pieter DE Backer,Severin Rodler,Karl F Kowalewski et al.
Pieter DE Backer et al.
Office-based transperineal laser ablation in patients with large prostates (≥80 mL): real-world evidence of safety and efficacy from a prospective single center cohort [0.03%]
办公室基于的经会阴激光消融治疗大型前列腺（≥80毫升）患者：来自前瞻性单中心队列的真实世界安全性和有效性证据
Paolo Polverino,Luisa Moscardi,Mattia Lo Re et al.
Paolo Polverino et al.
Transperineal laser ablation (TPLA) is emerging as a minimally invasive, office-based treatment for benign prostatic obstruction, but there is still a lack of evidence regarding its results in large prostates. The aim of this work was to ev...